Evidence map›Paper›PMID 21191005›Full record

ArticleJournal of virology2011

Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.

Kristina Abel, Joy Martinez, Yujuan Yue, Simon F Lacey, Zhongde Wang, Lisa Strelow, Anindya Dasgupta, Zhongqi Li, Kimberli A Schmidt, Kristie L Oxford and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Kristina AbelCalifornia National Primate Research Center, University of California, Davis, County Rd. 98 and Hutchison Dr., Davis, CA 95616-8542, USA.
Joy Martinez
Yujuan Yue
Simon F Lacey
Zhongde Wang
Lisa Strelow
Anindya Dasgupta
Zhongqi Li
Kimberli A Schmidt
Kristie L Oxford
Basel Assaf
Jeffrey A Longmate
Don J Diamond
Peter A Barry
University of California, Davis · USBeckman Research InstituteCity of Hope · US

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Vaccine-Induced Immunity to CMVP01CA030206 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI FORMAN, STEPHEN J · 1985 to 2010
$31.8M
Peptide Vaccine To Prevent CMV Disease After HSCTR01CA077544 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI DIAMOND, DON J · 1998 to 2017
$5.6M
Evaluation of Protective CMV Vaccines in Rhesus MacaquesR01AI063356 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, DIAMOND, DON J · 2005 to 2014
$4.6M
NCI NIH HHS CA030206NCI NIH HHS CA033572NCI NIH HHS CA77544NCI NIH HHS P01 CA030206NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA077544NCRR NIH HHS P51 RR000169NCRR NIH HHS RR000169NIAID NIH HHS AI063356NIAID NIH HHS R01 AI063356
6 · The paper itself

Abstract

The use of animal models of human cytomegalovirus (HCMV) infection is critical to refine HCMV vaccine candidates. Previous reports have demonstrated that immunization of rhesus monkeys against rhesus cytomegalovirus (RhCMV) can reduce both local and systemic replication of RhCMV following experimental RhCMV challenge. These studies used prime/boost combinations of DNA expression plasmids alone or DNA priming and boosting with either inactivated virion particles or modified vaccinia virus Ankara (MVA) expressing the same antigens. Viral outcomes included reduced RhCMV replication at the site of subcutaneous inoculation and RhCMV viremia following intravenous inoculation. Since shedding of cytomegalovirus from mucosal surfaces is critical for horizontal transmission of the virus, DNA priming/MVA boosting was evaluated for the ability to reduce oral shedding of RhCMV following subcutaneous challenge. Of six rhesus monkeys vaccinated exclusively against RhCMV glycoprotein B (gB), phosphoprotein 65 (pp65), and immediate-early 1 (IE1), half showed viral loads in saliva that were lower than those of control monkeys by 1 to 3 orders of magnitude. Further, there was a strong association of memory pp65 T cell responses postchallenge in animals exhibiting the greatest reduction in oral shedding. These results highlight the fact that a DNA/MVA vaccination regimen can achieve a notable reduction in a critical parameter of viral replication postchallenge. The recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was reduced by 50% in the individuals receiving the vaccine is consistent with the results of this study suggesting that additional immunogens are likely essential for maximum protection in an outbred human population.

Indexed as

Virus SheddingAnimalsCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Models, AnimalFemaleImmunization, SecondaryMacaca mulattaMaleMouth MucosaPrimate DiseasesSalivaVaccinationVaccines, DNAViral LoadCytomegalovirus VaccinesVaccines, DNA

Identifiers

PMID21191005
PMCPMC3067943
OpenAlexW2096690890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.